Literature DB >> 3207564

Polymorphism of debrisoquine hydroxylation among Finns and Lapps.

P Arvela1, M Kirjarinta, M Kirjarinta, N Kärki, O Pelkonen.   

Abstract

Debrisoquine hydroxylation polymorphism was studied in 155 Finns and 70 Lapps. The frequency of the poor metabolizer phenotype was 3.2% among Finns (95% confidence interval 0.4-6.0%) and 8.6% among Lapps (95% confidence interval 2.0-15.1%).

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3207564      PMCID： PMC1386638          DOI： 10.1111/j.1365-2125.1988.tb05301.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  13 in total

1.  Isoniazid inactivation in Finns and Lapps as demonstrated by various methods.

Authors:  H Tittinen; M J Mattila; A W Eriksson
Journal:  Am Rev Respir Dis       Date:  1973-08

2.  Demography of the Skolt Lapps in Northern Finland.

Authors:  T Lewin; A Rundgren; H Forsius; A W Eriksson
Journal:  Suom Hammaslaak Toim       Date:  1971

Review 3.  The genetic control of drug oxidation in the liver.

Authors:  P Dayer; L Balant; J Fabre
Journal:  Int J Clin Pharmacol Res       Date:  1983

4.  Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.

Authors:  M S Lennard; J H Silas; A J Smith; G T Tucker
Journal:  J Chromatogr       Date:  1977-03-11

Review 5.  The Upjohn Award Lecture 1981/La Conférence Upjohn 1981. The metabolism of xenobiotics in different populations.

Authors:  W Kalow
Journal:  Can J Physiol Pharmacol       Date:  1982-01       Impact factor: 2.273

6.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

7.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.

Authors:  E Steiner; L Iselius; G Alván; J Lindsten; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

8.  The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.

Authors:  D A Evans; D Harmer; D Y Downham; E J Whibley; J R Idle; J Ritchie; R L Smith
Journal:  J Med Genet       Date:  1983-10       Impact factor: 6.318

Review 9.  Clinical pharmacokinetics of isoniazid.

Authors:  W W Weber; D W Hein
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

10.  Inhibitory effects of neuroleptics on debrisoquine oxidation in man.

Authors:  E K Syvälahti; R Lindberg; J Kallio; M De Vocht
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335
View more
  4 in total

1.  The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.

Authors:  H Sakai; S Kobayashi; K Hamada; S Iida; H Akita; E Tanaka; E Uchida; H Yasuhara
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

2.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Debrisoquine oxidation polymorphism in a Tasmanian population.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer.

Authors:  A Hirvonen; K Husgafvel-Pursiainen; S Anttila; A Karjalainen; H Vainio
Journal:  Environ Health Perspect       Date:  1993-10       Impact factor: 9.031
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.